Theoretical and in-vitro study of Spa... - Advanced Prostate...

Advanced Prostate Cancer

22,006 members27,595 posts

Theoretical and in-vitro study of Sparganii and Curcumin together for castration resistant prostate cancer

Graham49 profile image
4 Replies

I’ve not heard of Sparganii (sparganium) before but it’s not new to TCM. This herb combination is apparently a classic TCM treatment for CRPC.

Wu, L., Chen, H., Long, Y. et al. Exploring the mechanism of action of Sparganii Rhizoma-Curcumae Rhizoma for in treating castration-resistant prostate cancer: a network-based pharmacology and experimental validation study. Sci Rep 14, 3099 (2024). doi.org/10.1038/s41598-024-...

Published 07 February 2024

DOI

doi.org/10.1038/s41598-024-...

“Abstract

Sparganii Rhizoma-Curcumae Rhizoma (SR-CR) is a classic drug pair for the treatment of castration-resistant prostate cancer (CRPC), but its mechanism has not been clarified. The study aims to elucidate the potential mechanism of SR-CR in the management of CRPC. The present study employed the TCMSP as well as the SwissTargetPrediction platform to retrieve the chemical composition and targets of SR-CR. The therapeutic targets of CRPC were identified through screening the GeneCards, Disgenet, and OMIM databases. Subsequently, the Venny online platform was utilized to identify the shared targets between the SR-CR and CRPC. The shared targets were enrichment analysis using the Bioconductor and Kyoto encyclopedia of genes and genomes (KEGG) databases. The active ingredients and core targets were verified through molecular docking and were validated using PC3 cells in the experimental validation phase. A total of 7 active ingredients and 1126 disease targets were screened from SR-CR, leading to a total of 59 shared targets. Gene Ontology (GO) analysis resulted in 1309 GO entries. KEGG pathways analysis yielded 121 pathways, primarily involving cancer-related signaling pathways. The results from molecular docking revealed stable binding interactions between the core ingredients and the core targets. In vitro cellular assays further demonstrated that SR-CR effectively suppressed the activation of the Prostate cancer signaling pathway in PC3 cells, leading to the inhibition of cell proliferation and promotion of apoptosis. The SR-CR exert therapeutic effects on CRPC by inhibiting cell proliferation and promoting apoptosis through the Prostate cancer signaling pathway.”

Written by
Graham49 profile image
Graham49
To view profiles and participate in discussions please or .
Read more about...
4 Replies
j-o-h-n profile image
j-o-h-n

Sure, Sparganii and meatballs.

Good Luck, Good Health and Good Humor.

j-o-h-n

Kaliber profile image
Kaliber in reply to j-o-h-n

lol

Professorgary profile image
Professorgary in reply to j-o-h-n

Don’t forget the garlic bread!

j-o-h-n profile image
j-o-h-n

Yep you're right! How could I forget wiping the plate clean.....(slaps self)....

Good Luck, Good Health and Good Humor.

j-o-h-n

Not what you're looking for?

You may also like...

Study reports direct targets of ivermectin in prostate cancer

Integrated analysis reveals FOXA1 and Ku70/Ku80 as direct targets of ivermectin in prostate cancer...

Recent study on Flubendazole for castration resistant PCa - Another repurposed drug

After reading donits recent post about ferroptosis I did a search on google Scholar and came up...

Combination of Statin/Vitamin D and Metastatic Castration-Resistant Prostate Cancer (CRPC) ...

New study below [1]. Note: AA = Abiraterone acetate/Zytiga "We conducted a post hoc analysis of...

Long term AR signaling‐targeted therapy with taxane sometimes associated with visceral metastasis in castration‐resistant prostate cancer

The present study was conducted to present androgen receptor signaling‐targeted therapy and taxane...

PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer

Abdallah Alzoubi 1 2 , Samir Al Bashir 3 , Aya Smairat 4 , Ahmad Alrawashdeh 5 , Husam...